Table 4 irAEs of different types and severity shown in completed clinical trials
From: Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives
Ref | Treatment | Patient(n) | irAEs | ||
|---|---|---|---|---|---|
Grade I-II(No.) | Grade III(No.) | Grade IV(No.) | |||
Giaccone et al. [61] | Pembrolizumab | 40 | AST increased (11) ALT increased (5) Alkaline phosphatase increased (10) Diarrhea (9) Arthralgia (4) Fever (5) Hypothyroidism (5) Rhinitis (4) Skin Rash (4) | AST increased (3) ALT increased (4) Dyspnea (3) Myalgia or myositis (3) | AST increased (2) ALT increased (1) Creatine phosphokinase Increased (2) Myocarditis (2) Hyperglycemia (1) |
Cho et al. [62] | Pembrolizumab | 33 | Dyspnea (11) Chest wall pain (10) Anorexia (7) Fatigue (7) Cough (6) Myalgia (3) Anemia (2) MG (1) | Hepatitis (3) Anemia (1) MG (1) Thyroiditis (1) | Hepatitis (1) MG (1) Myocarditis (3) |
Rajan et al. [63] | avelumab | 8 | Tumor pain (1) Extremity pain (1) Fever (2) Chills (1) Fatigue (4) | Autoimmune disorder (3) | Autoimmune disorders (2) Hypokalemia (1) |
Katsuya et al. [64] | Nivolumab | 15 | Adrenal insufficiency (1) Rash maculopapular (4) AST increased (8) ALT increased (3) Hypothyroidism (1) Diarrhea (3) Creatine phosphokinase increased (3) Creatinine increased (3) | AST increased (1) | Not available |